Longeveron (LGVN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 May, 2026Executive summary
Annual meeting scheduled for July 1, 2026, to be held virtually for shareholder participation.
Proxy materials are provided online to reduce costs and environmental impact.
Voting matters and shareholder proposals
Election of three directors: Stephen H. Willard, Leah Rush Cann, and Deborah Ascheim.
Proposal to increase authorized Class A common stock to 175,000,000 shares.
Proposal for a reverse stock split at a ratio between 1:2 and 1:20, at the Board's discretion.
Amendment to the 2021 Incentive Award Plan to add 5,000,000 shares.
Ratification of CBIZ CPAS P.C. as independent auditor for the year ending December 31, 2026.
Proposal to adjourn the meeting if more time is needed to solicit votes for Proposals 2 and 3.
Board of directors and corporate governance
Board recommends voting FOR all director nominees and management proposals.
Latest events from Longeveron
- Key proposals include director elections, share increases, and a reverse stock split to maintain listing.LGVN
Proxy filing20 May 2026 - Net loss narrowed to $4.7M in Q1 2026, but future operations require new funding and partnerships.LGVN
Q1 202619 May 2026 - Capital-light strategy and licensing focus position laromestrocel for major value inflection in 2026.LGVN
Investor presentation13 May 2026 - Annual meeting covers director elections, share structure changes, incentive plan, and auditor ratification.LGVN
Proxy filing5 May 2026 - HLHS Phase 2b data and PRV eligibility position laromestrocel for major value inflection.LGVN
Investor presentation4 May 2026 - Biotech registers resale of shares amid financial uncertainty and ongoing clinical development.LGVN
Registration filing10 Apr 2026 - Laromestrocel shows strong clinical progress and regulatory momentum across multiple indications.LGVN
Investor presentation1 Apr 2026 - Positive clinical progress in stem cell therapies for rare and aging-related diseases.LGVN
Investor presentation18 Mar 2026 - $15M financing extends runway as pivotal HLHS trial nears, despite 50% revenue drop and higher losses.LGVN
Q4 202517 Mar 2026